Evidence map›Paper›PMID 29491151›Full record

ArticleJournal of virology2018

Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.

Manickam Ashokkumar, Shambhu G Aralaguppe, Srikanth P Tripathy, Luke Elizabeth Hanna, Ujjwal Neogi

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. In vivo evolution of env in SHIV-AD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Deciphering DNA Methylation in HIV Infection.Frontiers in immunology · 2021
    Review
  13. Article
  14. Article
  15. AnData in brief · 2020
    Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Manickam AshokkumarDepartment of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Shambhu G AralaguppeDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Srikanth P TripathyDepartment of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India.
Luke Elizabeth HannaDepartment of HIV/AIDS, National Institute for Research in Tuberculosis, Chennai, India hannatrc@yahoo.com ujjwal.neogi@ki.se.
Ujjwal NeogiDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden hannatrc@yahoo.com ujjwal.neogi@ki.se.ORCID https://orcid.org/0000-0002-0844-3338
Karolinska Institutet · SENational Institute of Research in Tuberculosis · INScience for Life Laboratory · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adequate information on the precise molecular and biological composition of the viral strains that establish HIV infection in the human host will provide effective means of immunization against HIV infection. In an attempt to identify the transmitted founder (TF) virus and differentiate the biological properties and infectious potential of the TF virus from those of the population of the early transmitted viruses, 250 patient-derived gp120 envelope glycoproteins were cloned in pMN-K7-Luc-IRESs-NefΔgp120 to obtain chimeric viruses. Samples were obtained from eight infants who had recently become infected with HIV through mother-to-child transmission (MTCT) and two adults who acquired infection through the heterosexual route and were in the chronic stage of infection. Among the 250 clones tested, 65 chimeric viruses were infectious, and all belonged to HIV-1 subtype C. The 65 clones were analyzed for molecular features of the envelope, per-infectious-particle infectivity, coreceptor tropism, drug sensitivity, and sensitivity to broadly neutralizing antibodies. Based on genotypic and phenotypic analysis of the viral clones, we identified 10 TF viruses from the eight infants. The TF viruses were characterized by shorter V1V2 regions, a reduced number of potential N-linked glycosylation sites, and a higher infectivity titer compared to the virus variants from the adults in the chronic stage of infection. CXCR6 coreceptor usage, in addition to that of the CCR5 coreceptor, which was used by all 65 chimeric viruses, was identified in 13 viruses. The sensitivity of the TF variants to maraviroc and a standard panel of neutralizing monoclonal antibodies (VRC01, PG09, PG16, and PGT121) was found to be much lower than that of the virus variants from the adults in the chronic stage of infection.

Indexed as

AdultAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAnti-HIV AgentsCCR5 Receptor AntagonistsCell LineCyclohexanesHEK293 CellsHIV-1HIV Envelope Protein gp120HIV InfectionsHumansInfantMaravirocReceptors, CXCR6Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAnti-HIV AgentsCCR5 Receptor AntagonistsCXCR6 protein, humanCyclohexanesHIV Envelope Protein gp120MaravirocReceptors, CXCR6Triazolesamino acid diversitycoreceptor tropismhuman immunodeficiency virusmother-to-child transmissionresistance to neutralizationtransmitted founder virus

Identifiers

PMID29491151
PMCPMC5899188
OpenAlexW2791811398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.